logo
Share SHARE
FONT-SIZE Plus   Neg

EU Approves Roche's Perjeta To Treat Metastatic Breast Cancer

Roche announced that it has received approval from European regulators for its perjeta drug to help treat breast cancer.

The approval comes from the European Medicines Agency and covers patients with previously untreated HER2-positive metastatic breast cancer. The drug is approved in combination with two other treatments - Herceptin and docetaxel - in adult patients who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease.

The European approval comes after a late-stage trial showed that the combination of perjeta, Herceptin and chemotherapy provided patients with a median of 6.1 months longer without their disease worsening. It also provided a 34 percent reduction in the risk of death compared to Herceptin and chemotherapy alone.

The company said that perjeta is now approved in the EU, the U.S., and Switzerland for the treatment of people with this form of breast cancer. Further country approvals are anticipated during 2013.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Halliburton Company (HAL) reported a loss from continuing operations of $2.4 billion, or $2.81 per share, in the first quarter of 2016, compared to a loss of $639 million or $0.75 per share, previous year. Halliburton recorded company-wide charges related primarily to asset impairments and severance... Pfizer Inc. (PFE) reported a profit for first-quarter 2016 that increased 27 percent from last year. Both earnings per share and revenue for the quarter beat analysts' expectations. The company raised its fiscal year 2016 guidance to reflect the strong operational performance. German auto giant BMW Group (BMW.L, BAMXF.PK, BAMXY.PK) reported Tuesday higher net profit in its first quarter, while EBIT, a key earnings metric, declined on weak automotive revenues. Sales volumes, however, increased from last year. Further, the company confirmed its fiscal 2016 forecast, expecting slight increases. BMW shares were losing around 3 percent in the morning trading in Germany.
comments powered by Disqus
Follow RTT